PCVX - Company ID 0001649094
The table below shows Vaxcyte, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$280.63M | -$166.27M | -$159.12M | -$47.69M | -$27.70M | -$13.21M |
| Capital expenditure | $2.11M | $5.42M | $5.68M | $5.61M | $2.92M | $1.25M |
| Investing cash flow | -$233.41M | $123.32M | -$451.07M | -$448.10M | $49.67M | -$173.39M |
| Dividends paid | - | - | - |
Vaxcyte, Inc. reported operating cash flow of -$655.58M for fiscal year 2025. That is down 44.8% from -$452.63M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow declined from -$30.47M (FY 2018) to -$655.58M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $601.58M | $759.00K | $818.20M | $41.56M | $111.02M | $487.00K |